Latest news with #DavidLebowitz
Business Insider
09-08-2025
- Business
- Business Insider
Citi Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)
Citi analyst David Lebowitz maintained a Hold rating on Pliant Therapeutics today and set a price target of $1.70. The company's shares closed today at $1.66. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Lebowitz is a 4-star analyst with an average return of 4.5% and a 55.91% success rate. Lebowitz covers the Healthcare sector, focusing on stocks such as Incyte, Alnylam Pharma, and Cogent Biosciences. In addition to Citi, Pliant Therapeutics also received a Hold from Oppenheimer's Jeff Jones in a report issued today. However, on the same day, Piper Sandler maintained a Buy rating on Pliant Therapeutics (NASDAQ: PLRX). The company has a one-year high of $16.10 and a one-year low of $1.10. Currently, Pliant Therapeutics has an average volume of 1.26M.
Yahoo
27-03-2025
- Business
- Yahoo
Exelixis' cabozantinib approval ‘certainly positive,' says Citi
Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of unresectable, locally advanced or metastatic pancreatic neuroendocrine tumors and extra-pancreatic NET in patients ages 12 or older, Citi analyst David Lebowitz tells investors in a research note. The label expansion, which was based on progression-free survival results in the placebo-controlled Phase 3 CABINET trial, which showed a median increase in PFS over placebo of 9.4 months for pNET and 4.5 months for epNET, marks the sixth FDA approval for Cabometyx in the U.S., the firm says. The approval is 'certainly positive' for the stock, but Citi notes that lack of clarity surrounding the size of the market opportunity in NET, and made no change to its Buy rating or $45 price target Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on EXEL: Disclaimer & DisclosureReport an Issue Exelixis announces FDA approval of Cabometyx treatment groups FDA approves cabozantinib for adults and pediatric patients with pNET and epNET Exelixis to present positive preclinical data across pipeline portfolio at AACR Exelixis price target raised to $40 from $38 at RBC Capital Wells Fargo downgrades Exelixis, says take profits after rally Sign in to access your portfolio
